Lilly Oncology President Anne White On Loxo Success, What’s To Come

New Approval And Novel BTK Drug Emerge After Cancer R&D Reconfiguration

White said the late 2019 creation of Loxo Oncology at Lilly to spearhead cancer R&D has exceeded her expectations. The executive also discussed COVID-19’s impact on drug sales and cancer screening. 

Eli Lilly logo sign - San Diego, California, USA - 2020
Lilly Oncology's partnership with the Loxo research group has been productive • Source: Shutterstock

The reconfiguration of Eli Lilly and Company’s oncology research and development under the umbrella of Loxo Oncology Inc. has worked out even better than expected, Lilly Oncology president Anne White told Scrip. The R&D team working at what has been rebranded Loxo Oncology at Lilly has delivered a new product Retevmo (selpercatinib) to the parent company’s commercial portfolio and generated positive results for the BTK inhibitor LOXO-305.

“It's actually exceeding my expectations already and it's still early days really, just kind of a year into this experience,”...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category